Study of serum ctx in 50 oral surgical patients treated with oral bisphosphonates

• Antonio J. Flichy-Fernández ^[2] ; Teresa Alegre-Domingo ^[2] ; Sandra González-Lemonnier ^[2] ; José Balaguer-Martínez ^[3] ; María Peñarrocha-Diago ^[3] ; Yolanda Jiménez-Soriano ^[4] ; David Peñarrocha-Diago ^[2] ; José V. Bagán-Sebastián ^[1]
  1. [1] Chairman of Stomatology. Valencia University Medical and Dental School. Head of the Service of Stomatology, Valencia University General Hospital. Valencia (Spain)
  2. [2] DDS. Master in Oral Surgery and Implantology. Collaborating Professor of the Master in Oral Surgery and Implantology. Valencia University Medical and Dental School
  3. [3] Associate Professor of Oral Surgery. Professor of the Master in Oral Surgery and Implantology. Valencia University Medical and Dental School
  4. [4] Collaborating Professor in Oral Medicine. Valencia University Medical and Dental School

  Mostrar afiliaciones +
• Localización: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, ISSN-e 1698-6946, Vol. 17, Nº. 3 (Mayo), 2012
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Objectives: To determine whether there is a relationship between the total BP dose administered and the variations in serum CTX concentration.

    Study design: The study included 50 patients requiring dental implant surgery and treated with oral BPs, seen in an Oral Surgery and Implantology Unit between January 2007 and June 2009. The patients were divided into two groups: those in which the medication was not suspended before obtaining the laboratory test sample, and those patients referred from other dental clinics in which BPs was suspended before reporting to our Unit. The total drug dosage administered and the total dose per kilogram body weight were evaluated for comparison with serum CTX. The data obtained were correlated to the osteonecrosis risk table developed by Marx et al. in 2007.

    Results: There were no significant differences between the two groups in relation to the total administered dose and the dose in mg/kg b.w. Likewise, in both groups no relationship was observed between the serum CTX value and the total administered dose or the dose in mg/kg b.w. No differences were found between the two patient groups regarding chemical osteonecrosis risk based on the criteria of Marx et al.

    Conclusions: No relationship was observed between the oral BP dose administered (total dose or expressed in mg/kg b.w.) and serum CTX concentration, and suspension of the medication did not influence the serum CTX levels.